Search

Displaying results 4281 - 4290 of 10000 in total
  1. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    to grow and produce anthrax toxins. … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and

    Categories: Amino Acids, Peptides, and Proteins
  2. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    In migraine, CGRP innervates pain-producing meningeal blood vessels and is released by trigeminal nerve stimulation. … Zavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally.

    Synonyms: 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-
  3. Drug

    Cretostimogene grenadenorepvec

    go.drugbank.com/drugs/DB05148
    Investigational

    CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. … It has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy.

  4. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    GAA to the lysosome, where it can perform its normal function. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

  5. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    Approved

    [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … [L64052] After intravenous injection, florquinitau F 18 crosses the blood-brain barrier and accumulates in brain regions containing tau NFTs, allowing their distribution to be visualized and interpreted

  6. Drug

    Tyloxapol

    go.drugbank.com/drugs/DB06439
    ApprovedInvestigational

    Tyloxapol is a non-ionic detergent often used as a surfactant.

    Categories: Cough and Cold Preparations, Compounds used in a research, industrial, or household setting
  7. Indication

    Iron Deficiency Anemia (IDA)

    go.drugbank.com/conditions/DBCOND0047602
    Drugs: Ascorbic acid · Cyanocobalamin · Ferric carboxymaltose · Ferric cation · Ferric derisomaltose · Ferric hydroxide +16 more
    Synonyms: Iron Deficiency and Anemia
  8. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist … Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).

  9. Drug

    Magnesium trisilicate

    go.drugbank.com/drugs/DB09281
    Approved

    Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.

    Categories: Aluminum and magnesium containing antacids
  10. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    Difelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. … [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665]